Logo for Elevation Oncology Inc

Elevation Oncology Investor Relations Material

Latest events

Logo for Elevation Oncology Inc

Study Update

Elevation Oncology
Logo for Elevation Oncology

Study Update

6 Aug, 2024
Logo for Elevation Oncology

Q2 2024

6 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Elevation Oncology Inc

Access all reports
Elevation Oncology, Inc. is a biotechnology company focused on the discovery and development of targeted cancer therapies. The company specializes in creating antibody-drug conjugates (ADCs) to treat patients with solid tumors that have significant unmet medical needs. Their lead candidate, EO-3021, targets the Claudin 18.2 protein, which is expressed in various cancers, including gastric and pancreatic cancers. Elevation Oncology aims to selectively deliver cytotoxic agents directly to cancer cells, thereby improving treatment efficacy while minimizing damage to healthy tissues. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.